RTP Mobile Logo
Virtual Consult: Current Cases and Emerging Research in the Management of Multiple Myeloma, Hodgkin and Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
Released August 2016

Proceedings from a CME symposium held at the 2016 ASCO Annual Meeting. Featuring perspectives from Drs Ranjana Advani, Stephen M Ansell, Christopher Flowers, Brad S Kahl, Sagar Lonial and Robert Z Orlowski. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of hematologic cancers, including lymphoma and multiple myeloma (MM).

    OVERVIEW OF ACTIVITY
    Hematologic cancers include the lymphomas, the leukemias, MM and other related disorders (eg, myelodysplastic syndromes, myeloproliferative diseases) stemming from lymphoid and myeloid progenitor cell lines. Taken together, it is estimated that approximately 171,550 new lymphoid, myeloid and leukemic cancer cases will be identified in the United States in the year 2016, and 58,320 individ­uals will die from these diseases. Of note, more than 60 drug products are currently labeled for use in the management of hematologic cancers with more than 70 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors. This is particularly true, however, within the realm of Hodgkin and non-Hodgkin lymphoma and MM, where the past several years have yielded a staggering number of important clinical and research advances.

    These video proceedings from a CME symposium held during the 2016 ASCO Annual Meeting feature discussions with leading researchers with an expertise in hematologic cancers regarding actual patient cases and related clinical research findings. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to not only improve clinicians’ knowledge of recent data related to the rapidly evolving hematologic oncology treatment landscape but also to provide them with practical perspectives to help them become better and more effective caregivers.

    LEARNING OBJECTIVES

    • Customize the use of induction, consolidation and maintenance therapeutic approaches for patients with MM in the post-transplant and nontransplant settings, considering patient- and disease-related factors, including cytogenetic profile.
    • Consider available research data and other clinical factors in the best-practice selection, sequencing or combining of carfilzomib and pomalidomide in the nonresearch care of patients with relapsed/refractory (R/R) MM.
    • Recognize the recent FDA approvals of daratumumab, elotuzumab, ixazomib and panobinostat, and effectively identify where and how these novel agents should be integrated into the clinical management of R/R MM.
    • Appreciate the FDA approvals of novel targeted agents — ibrutinib, idelalisib, obinutuzumab and venetoclax — for the treatment of newly diagnosed and R/R chronic lymphocytic leukemia, and discern how these therapies can be appropriately integrated into the clinical management of standard- and high-risk disease.
    • Consider existing and emerging clinical research data in the formulation of therapeutic recommendations for patients with newly diagnosed and R/R follicular lymphoma.
    • Customize the selection of systemic therapy for patients with newly diagnosed and progressive mantle-cell lymphoma, recognizing the additions of bortezomib, ibrutinib and lenalidomide as FDA-endorsed options.
    • Utilize emerging research information on the use of novel prognostic and predictive clinical and molecular markers to aid in treatment decision-making for patients with newly diagnosed and R/R diffuse large B-cell lymphoma.
    • Incorporate new therapeutic strategies into the best-practice management of newly diagnosed and R/R Hodgkin lymphoma.
    • Communicate the benefits and risks of evidence-based systemic and targeted treatments to patients with advanced cutaneous or peripheral T-cell lymphoma.
    • Assess the ongoing clinical trials evaluating novel investigational approaches for Hodgkin and non-Hodgkin lymphoma and MM, and obtain consent from appropriate patients for study participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of this CME activity enables the participant to earn up to 2.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCOHem16/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Ranjana Advani, MD
    Professor of Lymphoma
    Stanford Cancer Center
    Stanford, California

    Advisory Committee: Genentech BioOncology; Contracted Research: Agensys Inc, a subsidiary of Astellas Pharma US, Celgene Corporation, Genentech BioOncology, Pharmacyclics LLC, an AbbVie Company, Regeneron Pharmaceuticals, Seattle Genetics, Takeda Oncology.

    Stephen M Ansell, MD, PhD
    Professor of Medicine
    Division of Hematology
    Mayo Clinic
    Rochester, Minnesota

    Contracted Research: Bristol-Myers Squibb Company, Celldex Therapeutics, Merck, Seattle Genetics.

    Christopher Flowers, MD, MS
    Associate Professor of Hematology and Medical Oncology
    Winship Cancer Institute
    Emory School of Medicine
    Atlanta, Georgia

    Consulting Agreements: Celgene Corporation, OptumRx Inc; Contracted Research: AbbVie Inc, Acerta Pharma, Celgene Corporation, Gilead Sciences Inc, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Takeda Oncology, TG Therapeutics Inc; Unpaid Consulting Agreements: Genentech BioOncology, Takeda Oncology.

    Brad S Kahl, MD
    Professor of Medicine
    Washington University School of Medicine
    St Louis, Missouri

    Advisory Committee: Roche Laboratories Inc, Takeda Oncology; Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology; Contracted Research: Abbott Laboratories.

    Sagar Lonial, MD
    Professor and Chair
    Department of Hematology and Medical Oncology
    Chief Medical Officer
    Winship Cancer Institute
    Emory University
    Atlanta, Georgia

    Advisory Committee and Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology.

    Robert Z Orlowski, MD, PhD
    Director, Myeloma Section
    Florence Maude Thomas Cancer Research Professor
    Departments of Lymphoma/Myeloma and Experimental Therapeutics
    Division of Cancer Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, FORMA Therapeutics, Janssen Biotech Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology; Contracted Research: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Spectrum Pharmaceuticals Inc, Takeda Oncology.

    CONSULTING ONCOLOGISTS — The following consulting oncologists (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Frances Albini-Valdes, MD
    University of Miami Health System
    Miami, Florida

    No relevant conflicts of interest to disclose.

    Lowell L Hart, MD
    Florida Cancer Specialists
    Fort Myers, Florida

    No relevant conflicts of interest to disclose.

    Erik J Rupard, MD
    The Reading Hospital and Medical Center
    West Reading, Pennsylvania

    No relevant conflicts of interest to disclose.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Agendia Inc, Amgen Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc. 

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP/Acerta Pharma, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc, Seattle Genetics and Takeda Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: August 2016
    Expiration date: August 2017

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):
Click below to select videos to play: